Skip to main content
. 2019 Nov 23;2019:5820839. doi: 10.1155/2019/5820839

Figure 2.

Figure 2

Cav-1 is necessary for KCa2.3 and KCa3.1 internalization from the PM. (a) Cav-1 levels were reduced in ECs treated with NP serum, which were reversed by VEGFR inhibition using anti-VEGFR1 and anti-VEGFR2 Abs. (b) Cav-1 levels in ECs treated with NP serum or PE serum, and in ECs treated with LPC. LPC enhanced Cav-1 levels in ECs in a concentration-dependent manner. (c) PM localization of Cav-1 was increased by oxidized LDL. (d) Coimmunoprecipitation showing the interaction between Cav-1 and KCa3.1 in ECs treated with NP or PE serum. Input is lysate without primary Ab. (e, f) Treatment with the Cav-1 inhibitor MβCD (1 mM) recovered KCa2.3 (e) or KCa3.1 (f) levels in ECs treated with PE serum or LPC. Blots shown are representative of three to six experiments performed with three to six different cultures. Bar graphs represent the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01.